Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2005-08-09 Annual Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Annual Report 2005
Annual Report Classification · 100% confidence The document is titled as an "Amendment No. 1 to Form 20-F," which is a registration statement filed with the SEC by foreign private issuers. The Form 20-F is used for annual reports and registration statements under the Securities Exchange Act of 1934. The document includes detailed financial data, management discussion, risk factors, directors and officers information, and financial statements references. It is a comprehensive report covering the company's financial performance and operations for the fiscal year ended December 31, 2004. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is the full report, not just an announcement or certification. Therefore, this filing corresponds to an Annual Report (10-K equivalent for foreign issuers).
2005-08-09 English
Immediate report on other matter
Regulatory Filings Classification · 95% confidence The document is a press release announcing the end of patient dosing in a Phase 2 clinical trial and the transition of the development program to another company. It contains no financial statements, regulatory filings, or detailed financial data. It is an update on clinical trial progress and partnership changes, not a financial report or regulatory filing. The document length is short (2221 characters) and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2005-08-09 Hebrew (modern)
Immediate report on other matter
Regulatory Filings Classification · 95% confidence The document is very short (1608 chars) and contains metadata typical of a regulatory filing announcement, including the company name, date (09/08/2005), and reference number. Crucially, it explicitly states 'Immediate report on other matter' and includes the line 'Attached file *BCubist9Aug05_isa.pdf*'. This structure indicates that the document itself is merely an announcement that a report (likely a press release or regulatory filing) is attached or available, rather than being the full content of a specific report type like 10-K, ER, or IR. According to Rule 2, this points to a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since it is an 'Immediate report on other matter' and doesn't fit the specific definitions of RPA (which usually announces the publication of a known report type), RNS is the most appropriate fallback for a general, immediate regulatory disclosure that doesn't fit other categories.
2005-08-09 English
Regulatory Filings 2005
Regulatory Filings Classification · 100% confidence The document is a comment letter from the SEC staff to XTL Biopharmaceuticals Ltd. regarding their Form 20-FR12G filing. It contains detailed comments on disclosures, requests for revisions, and instructions for filing amendments. The letter references specific sections of the Form 20-F and discusses compliance and disclosure issues. It is not the actual Form 20-F report itself, nor is it a financial report or earnings release. It is a regulatory review letter related to a regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which includes compliance documents and correspondence with regulators.
2005-08-03 English
Immediate report on other matter
Board/Management Information Classification · 95% confidence The document is an announcement from XTL Biopharmaceuticals Ltd. about the appointment of Michael Weiss as Non-Executive Chairman following an Extraordinary General Meeting (EGM). It mentions shareholder approval of resolutions and changes in the board leadership. There is no financial data, no detailed report, no earnings information, or regulatory filings beyond the management change. The key content is the appointment of a new chairman and the confirmation of board changes. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, not on financial results or other report types.
2005-08-01 Hebrew (modern)
Immediate report on other matter
Regulatory Filings Classification · 95% confidence The document is very short (1617 characters) and explicitly states 'Immediate report on other matter' and 'Attached file *15-05EGMstatement1Aug05_isa.pdf*'. The title within the body is '*Extraordinary General Meeting Statement*'. This indicates the document is an announcement about the availability of a statement related to an Extraordinary General Meeting (EGM), rather than the full statement itself. Since the content is an announcement regarding a meeting statement, and there is no specific code for EGM announcements, the most appropriate classification is Report Publication Announcement (RPA) because it announces the publication of a related document. If the attached file were the actual content, AGM-R might apply, but as a short announcement pointing to a file, RPA is better, or RNS if RPA is too specific. Given the context of an EGM statement being announced, RPA fits well as it signals the publication of a report/statement. However, since the content is about an EGM statement, and the definitions include AGM-R for AGM materials, an EGM statement is closely related. Given the 'Menu vs Meal' rule, this is the announcement (menu), not the report (meal). RPA is for announcing the publication of reports. Since the document explicitly mentions an 'Extraordinary General Meeting Statement', and RPA is the best fit for announcing a report's publication, I will select RPA. If the document was the actual EGM material, AGM-R would be considered.
2005-08-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.